Clinical Trials
Below are current clinical trials.
259 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
This study will be a retrospective and prospective analysis of patients with Post-COVID-19 symptoms that persist for greater than 28 days that are seen in the PCoCC (Post COVID Care Clinic), CARP, Pulmonary for post COVID clinic, Neurology, or approval by the MAGPIES research group.
Data for the registry will be aggregated from the EHR and by questionnaires. This data can be used to better guide strategic and tactical decisions as clinicians and healthcare managers respond to the rapidly evolving Post-COVID-19 patients.
The biobank will be optional for the participant and is designed to prospectively collect research biospecimens from Post-COVID-19 with symptoms that persist for greater than 28 days.
-
Rochester, Minn.
The purpose of this study is to prospectively clarify the long-term consequences of SARS-CoV-2 infection in the CNS with multi-modal magnetic resonance (MR) imaging tracking structural, microstructural, vascular and biochemical changes.
COVID-19 increases the risk of developing long-term inflammatory, neurodegenerative and cerebrovascular consequences.
-
Rochester, Minn.
The objective is to obtain and report outcome data for adult subjects who received systemic antifungal therapy (AFT) for the treatment of invasive mucormycosis (IM) or invasive aspergillosis (IA) caused by a non-fumigatus species.
-
Rochester, Minn.
The purpose of this study is to develop a test that can be used routinely to detect and identify Candida auris from surveillance skin swabs.
-
Rochester, Minn.
The purpose of this study is to assess the effectiveness and safety of giving anti-influenza immune plasma, as an addition to standard of care antivirals, to patients hospitalized with severe influenza A infection.
-
Scottsdale/Phoenix, Ariz.
This open-label study will evaluate safety, pharmacokinetics and efficacy of a 12 or 24 week regimen of ombitasvir/ABT-450/ritonavir and dasabuvir with or without ribavirin in HCV-genotype 1-infected subjects with an Estimated Glomerular Filtration Rate (eGFR) <30, including those on hemodialysis.
-
Rochester, Minn.
The purpose of this study is to identify correlates of healthcare-seeking behavior in patients with ACS and CHF and its association with psychosocial and health outcomes.
-
Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The study seeks to understand the impacts the COVID pandemic has brought to the communities, how communities are coping and how we can build resilience to prepare for future health crises.
-
Rochester, Minn.
The purpose of this study is to determine differences in microbiota composition in volunteers with and without Rome IV defined Campylobacter jejuni PI-IBS, and to determine differences in peripheral metabolites, proteins and lipids in volunteers with and without Rome IV defined Campylobacter jejuni PI-IBS.
-
Jacksonville, Fla.
This will be a prospective study of patients with IBD at Mayo Clinic initially in Jacksonville with possible subsequent extension to other Mayo sites. We will evaluate the immunogenicity of commercially available COVID-19 vaccines and compare vaccine response among the groups based on their immunosuppressive regimens. We will divide the immunosuppressive regimens into presumed high vaccine responders Group A and presumed low vaccine responders Group B. We will also assess for adverse reactions to the vaccine and compare with the reported rates in the clinical trials that led to approval of these vaccines.